Xeloda for Metastatic Breast Cancer

An oral chemotherapy option

In This Article

Xeloda (capecitabine) is an oral chemotherapy drug approved by the U.S. Food and Drug Administration (FDA) to treat metastatic breast cancer in people who have not responded to medications like Taxol (paclitaxel), Taxotere (docetaxel), Adriamycin (doxorubicin), or anthracycline-containing chemotherapy options. Xeloda can be given alone or with other drugs.

Indications

If you have already been treated with paclitaxel and Adriamycin (doxorubicin) and had no response, your doctor may recommend that you take Xeloda by itself.

If you have had no response from treatment with anthracyclines, your doctor may instead recommend that you take Xeloda and Taxotere.

In addition to metastatic breast cancer, Xeloda is used to treat metastatic colon, rectal, and prostate cancers.

How It Works

Xeloda kills cancer cells by imitating part of a cancer cell's genes. This makes the cell die before it can divide, which slows or stops cancer from growing.

Efficacy

Studies show this drug appears to:

  • Prolong both overall survival and disease-free survival in people with metastatic HER2-negative breast cancer, as a post-surgical treatment
  • In combination with lapatinib, improve overall survival and progression-free survival in HER2-positive breast cancer that has progressed on trastuzumab
  • In combination with lapatinib, improve HER2-positive breast cancer that has metastasized to the brain, when local therapy isn't effective and re-irradiation isn't feasible
  • In combination with standard chemotherapy, improve overall survival and disease-free survival in triple-negative breast cancer (although studies are mixed on this point)

While studies show that it can be effective for many people, Xeloda may not be as effective as some other drugs, and adding it to other chemotherapy drugs may increase the risk of side effects.

Dosage and Administration

Xeloda is an oblong, peach-colored pill given in either 150 milligram (mg) or 500 mg dosages. It's generally taken twice a day, ideally about 30 minutes after a meal and with plenty of water.

It's taken on a cyclical dosage schedule that's two weeks on, one week off, then two weeks on. Your doctor will decide how long you'll stay on this cycle.

Side Effects

Common side effects of Xeloda include:

  • Diarrhea
  • Nausea
  • Vomiting
  • Oral mucositis (sores in your mouth, tongue, and throat)
  • Stomach pain
  • Low appetite
  • Dehydration
  • Skin rash or dry, itchy skin
  • Dizziness
  • Fatigue
  • Headache
  • Swelling of the feet, ankles, or hands
  • Neuropathy (tingling of fingers and toes)

When taking Xeloda, try to stay hydrated by drinking more water than you are used to. Doctors often recommend you drink two to three quarts of water every 24 hours. You may be told to skip alcohol or caffeine, as these can dehydrate you. If you experience mouth or tongue sores, replace your usual toothbrush with a soft-bristled kind.

If you experience dizziness, plan to take it easy when you're taking Xeloda. If you're extremely nauseous, your doctor may recommend anti-nausea medications to help you through.

The side effects of Xeloda may be different if you are taking it along with Taxotere or other chemotherapy drugs. Be sure to report all of your side effects to your doctor. Note the dates and times they occur, and rank the severity of each symptom.

Call your doctor and stop taking Xeloda immediately if you have these symptoms:

  • Severe diarrhea
  • Severe vomiting
  • Painful sores in your mouth and tongue
  • Fever

Risks

If you use coumadin or warfarin (blood thinning medications), Xeloda can cause your blood to thin more, putting you in danger of extensive bleeding. Tell your doctor if you take any blood thinner. You may need to take a lower dose of Xeloda.

If you are 80 years old or older, Xeloda may cause more diarrhea, nausea, and vomiting than in younger people.

Common cuts are more complicated when you take Xeloda, so it's important to minimize the risk of getting a cut. Doctors usually recommend you switch to an electric razor for shaving for this reason.

In addition, you may find yourself feeling more susceptible to sunlight while on this drug. Avoid sun exposure and use a good sunscreen whenever you are outside.

Contraindications

You should not take Xeloda if:

  • You are allergic to 5-fluorouracil (5-FU)
  • You have kidney or liver problems
  • You are breastfeeding
  • You are pregnant or may become pregnant

In addition, about 1 in 20 people have specific liver metabolism enzymes that lead to a slower breakdown of the drug. These people can have significant side effects like severe diarrhea and extensive palmar-plantar erythrodysesthesia, which includes sores on the palms and feet. These people should not take Xeloda.

Was this page helpful?

Article Sources

Verywell Health uses only high-quality sources, including peer-reviewed studies, to support the facts within our articles. Read our editorial policy to learn more about how we fact-check and keep our content accurate, reliable, and trustworthy.
  1. Genentech USA, Inc. XELODA (capecitabine) tablets [package insert]. U.S. Food and Drug Administration. Revised March 2015. 


  2. Natori A, Ethier JL, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trialsEur J Cancer. 2017 May;77:40-47. doi:10.1016/j.ejca.2017.02.024


  3. Madden R, Kosari S, Peterson GM, Bagheri N, Thomas J. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic reviewInt J Clin Parmacol Ther. 2018 Feb;56(2):72-80. doi:10.5414/CP203123


  4. Petrelli F, Ghidini M, Lonati V, et al. The efficacy of lapatinib and capecitabine in HER-2 positive breast cancer with brain metastases: A systematic review and pooled analysisEur J Cancer. 2017 Oct;84:141-148. doi:10.1016/j.ejca.2017.07.024


  5. Natori A, Ethier JL, Amir E, Cescon DW. Capecitabine in early breast cancer: A meta-analysis of randomised controlled trialsEur J Cancer. 2017 May;77:40-47. doi:10.1016/j.ejca.2017.02.024


Additional Reading